Abuse-Deterrent Formulations Exempt From Medicaid Rebates Under Bill
This article was originally published in The Pink Sheet Daily
Comprehensive opioid addiction legislation is considered by House-Senate conference committee on July 6.
You may also be interested in...
Opioid formulations with abuse-deterrent properties will be exempt from Medicaid price-inflation rebates if they meet FDA standards, Centers for Medicare and Medicaid Services says in guidance to manufacturers.
Addiction prevention legislation empowers Medicare drug plans to restrict prescriber, pharmacy access to opioids for ‘at risk’ beneficiaries.
Inter Parfums is targeting deals with "evergreen-type" brands doing around $50m in annual sales that could benefit from its expertise and extensive distribution network. The firm’s first-quarter sales totaled $198.5m, an increase of 11% compared with 2019 levels and 37% versus the prior-year period.